Biomarkers Consortium - Sarcopenia as a Valid Biomarker for Identifying Individuals at Risk of Disability

The Biomarkers Consortium’s Sarcopenia as a Valid Biomarker for Identifying Individuals at Risk of Disability (Sarcopenia 2 Project) seeks to establish evidence-based cut-points for muscle mass and strength and determine their predictive validity for clinically meaningful outcomes (such as mobility, fractures, hospitalization and death); evaluate relative strength as a discriminator for mobility limitation and incident disability; and explore the potential usefulness of sarcopenia as a clinical endpoint in randomized clinical trials. The concept of sarcopenia as a clinical biomarker to identify older adults at risk of physical disability and poor health outcomes is based on the measurement of lean soft tissue mass and muscle strength. It has considerable appeal to the practicing clinicians who care for these patients and to the pharmaceutical companies that are engaged in the development of therapies to prevent or to treat functional limitations in older adults.

Sarcopenia 2 builds on the results of the Sarcopenia 1 Project, which developed the initial sarcopenia criteria for predicting physical disability and clinically meaningful patient-important health outcomes. The Sarcopenia 2 Project will pool together additional clinical data sets from epidemiologic studies and clinical trials of older adults, in whom the disability rates are higher and the potential for treatment may be much greater, to validate and extend the findings from Sarcopenia 1.

Goals

  • Establish evidence-based cut-points for muscle mass and strength and determine their predictive validity for clinically meaningful outcomes (such as mobility, fractures, hospitalization and death).
  • Evaluate relative strength as a discriminator for mobility limitation and incident disability.
  • Explore the potential usefulness of sarcopenia as a clinical endpoint in randomized clinical trials.

Partners

Abbott
Alliance for Aging Research
Astellas Pharma Inc.
Boston Medical Center
Columbia University
Dairy Research Institute
Food and Drug Administration
Harvard
Hebrew SeniorLife
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
National Institute on Aging (NIA)
Partners Healthcare
Pfizer Inc.
Regeneron Pharmaceuticals, Inc.
San Francisco Coordinating Center
Tufts
University of California
University of Central Florida
University of Connecticut
University of Florida
University of Maryland
University of Pittsburgh

Contact

Tania Kamphaus, Scientific Program Manager, Metabolic Disorders, TKamphaus@fnih.org

Lilit Vardanian, Scientific Project Manager, Metabolic Disorders, lvardanian@fnih.org